Neuspera Medical, a San Jose, CA-based neuromodulation company, has raised $23 million in Series D funding. The round was led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Innovation Ventures, and another strategic investor.

The funds will be used to further enhance Neuspera Medical’s growth through the anticipated U.S. Food and Drug Administration (FDA) premarket approval (PMA) of its neuromodulation system. Led by CEO Steffen Hovard, Neuspera Medical is dedicated to developing implantable medical devices aimed at improving the lives of patients suffering from chronic illnesses. The company’s flagship product is an ultra-miniaturized, minimally invasive implant designed to provide patients with personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).

The Neuspera System features an ultra-miniaturized pulse generator attached to an electrode array, offering a discreet solution for managing UUI and improving patient outcomes.